What is Azilsartan Prescribed For?
Azilsartan medoxomil, marketed as Edarbi, is primarily approved for the treatment of hypertension, or high blood pressure [1]. It belongs to a class of drugs known as angiotensin II receptor blockers (ARBs) [1].
Are There Any Approved Off-Label Uses for Azilsartan?
Currently, there are no FDA-approved off-label uses for azilsartan [2]. Off-label use means a drug is prescribed for a condition or in a dosage not officially approved by regulatory bodies like the FDA. While healthcare providers may prescribe medications off-label based on their professional judgment and scientific evidence, these uses are not supported by formal regulatory review [2].
What Conditions Might Azilsartan Be Investigated For?
Research has explored azilsartan's potential in other cardiovascular conditions, though these are not yet established uses. Studies have investigated its effects on:
* Cardiorenal Protection: Azilsartan has shown potential in protecting the heart and kidneys, particularly in patients with conditions like heart failure or chronic kidney disease [3][4]. Some research suggests it may offer greater cardiorenal benefits compared to other ARBs [3].
* Pulmonary Arterial Hypertension (PAH): Preliminary investigations have explored azilsartan's role in PAH, a condition characterized by high blood pressure in the arteries of the lungs [5].
It is important to note that these are areas of ongoing research, and these potential uses have not been approved by regulatory agencies.
How Does Azilsartan Work?
Azilsartan functions by blocking the action of angiotensin II, a substance in the body that narrows blood vessels [1]. By inhibiting angiotensin II, azilsartan allows blood vessels to relax and widen, which in turn lowers blood pressure [1].
What is the Patent Status of Azilsartan?
The primary patents for azilsartan medoxomil have expired or are nearing expiration in many regions. DrugPatentWatch.com tracks these patent expirations, which can influence the availability of generic versions of the drug [6]. Patent expiration dates are crucial for understanding when competition from generic manufacturers may increase.